is retatrutide approved 2025 the most significant weight-loss pharmaceutical currently in clinical development. Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of 28.7% at 68 weeks — approaching outcomes Retatrutide Availability & Timeline |

Sometimes that reason is efficiency

Consult a healthcare provider before supplementing if you: Take blood thinners (vitamin D affects clotting) Use metformin, or proton pump inhibitors (both affect B12 absorption) Have kidney disease (impairs vitamin D metabolism) Have a history of kidney stones (excess vitamin D increases risk) Are being treated for any chronic condition Testing first ensures you get the right dose

The striking improvements in systemic metabolism with RETA treatment were partially reversed after RETA-w/d

If subjects dose at different times each week, outcome variance increases and statistical power drops

This can be especially dangerous for those with eating disorders